Barclays analyst Gena Wang downgrades Arcturus Therapeutics (NASDAQ:ARCT) from Equal-Weight to Underweight and lowers the price target from $33 to $25.
Crude oil prices hit multi-year highs this week above $70 pre barrel on optimism surrounding summer reopening and travel demand.
On Friday, one Wall Street analyst adjusted his oil stock coverage ahead of what could be a big summer for oil stocks.
The Analyst: Morgan Stanley analyst Devin McDermott issued the following oil stock rating changes: